<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511899</url>
  </required_header>
  <id_info>
    <org_study_id>BTS850/15</org_study_id>
    <nct_id>NCT02511899</nct_id>
  </id_info>
  <brief_title>Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function</brief_title>
  <official_title>Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vital Solutions Swiss AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vital Solutions Swiss AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the acute effects of a single dose of Careless™, a Mangifera indica fruit&#xD;
      powder on cutaneous microcirculation and endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta change of dermal microcirculation before and after intake (1h, 2h, 3h, 4h and 6h post) measured by O2C technology</measure>
    <time_frame>baseline before intake at the same day and 1hour, 2hour, 3hour, 4hour and 6hour post intake</time_frame>
    <description>Change over time for microcirculation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta change of endothelial function using EndoPAT™ (baseline and 3hour post)</measure>
    <time_frame>baseline before intake at the same day and 3 hours post intake</time_frame>
    <description>Changes over time of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, number of participants with adverse events</measure>
    <time_frame>after 6 hours of intake</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Microcirculation</condition>
  <condition>Metabolism</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Mango fruit powder 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mango fruit powder 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mango fruit powder 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mango fruit powder 300mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mango fruit powder</intervention_name>
    <description>Dietary supplement; Mango fruit powder</description>
    <arm_group_label>Mango fruit powder 100mg</arm_group_label>
    <arm_group_label>Mango fruit powder 300mg</arm_group_label>
    <other_name>Careless</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations&#xD;
&#xD;
          -  Subject is in good physical and mental health as established by medical history,&#xD;
             physical examination, electrocardiogram, vital signs, results of biochemistry and&#xD;
             haematology&#xD;
&#xD;
          -  Healthy normal skin condition at the forearm&#xD;
&#xD;
          -  BMI: 19-30 kg/m2&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age ≥ 40 and ≤ 70 years&#xD;
&#xD;
          -  Nonsmoker&#xD;
&#xD;
          -  Able and willing to follow the study protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant history, presence of any medical disorder or chronic intake of&#xD;
             medication/dietary supplements (e.g. polyphenols, L-Arginine, Niacin, medication of&#xD;
             haemodilution, blood flow stimulating products like Aspirin) potentially interfering&#xD;
             with this study at screening&#xD;
&#xD;
          -  For this study clinically relevant abnormal laboratory, vital signs or physical&#xD;
             findings at screening&#xD;
&#xD;
          -  Atopic dermatitis or affected skin at the forearm&#xD;
&#xD;
          -  Regular consumption of caffeine &gt; 275 mg (equivalent to 3-4 cups of coffee or 9 cups&#xD;
             of black tea)&#xD;
&#xD;
          -  Change of dietary habits within the 2 weeks prior to screening (for instance start of&#xD;
             a diet high in vegetables and fruits (≥ 5 portions per day))&#xD;
&#xD;
          -  Diet high in vegetables and fruits ≥ 5 portions per day&#xD;
&#xD;
          -  Participants anticipating a change in their lifestyle or physical activity levels&#xD;
             since this may also influence the results&#xD;
&#xD;
          -  Subjects not willing to avoid polyphenol rich foods and abstain from beverages&#xD;
             containing caffeine the day prior to visit 1 and 2&#xD;
&#xD;
          -  Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24&#xD;
             hours prior to and during visit 1 and 2&#xD;
&#xD;
          -  Sunbathing or the use of sun-beds 2 weeks prior to study days&#xD;
&#xD;
          -  Injury on the finger, influencing the EndoPAT™ measurement&#xD;
&#xD;
          -  Subjects with history of drug, alcohol or other substances abuse, or other factors&#xD;
             limiting their ability to co-operate during the study&#xD;
&#xD;
          -  Known hypersensitivity to the study product or to single ingredients&#xD;
&#xD;
          -  Pregnant subject or subject planning to become pregnant during the study;&#xD;
             breast-feeding subject.&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  Known acute or chronic hepatitis B and C infection&#xD;
&#xD;
          -  Blood donation within 4 weeks prior to visit 1 or during the study&#xD;
&#xD;
          -  Subject involved in any clinical or food study within the preceding month&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Reule, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioTeSys GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microcirculation</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>human study</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>Mangifera indica</keyword>
  <keyword>Careless</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

